Navigation Links
Peramivir Phase 2 Data for the Treatment of Outpatient Influenza to be Presented at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
Date:10/20/2008

ressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Some of the factors that could affect the forward-looking statements contained herein include that our belief that many subjects in the Phase 2 clinical trials of peramivir did not receive adequate dosing by intramuscular injection may not be correct, that HHS and the Food & Drug Administration (FDA) may not agree with our analysis, that HHS may further condition, reduce or eliminate future funding of the peramivir program, that ongoing peramivir clinical trials may not be successful, that the peramivir program may not be successful, that the pivotal trial with forodesine HCl in cutaneous T-cell lymphoma (CTCL) may not meet its endpoint, that development and commercialization of forodesine HCl in CTCL may not be successful, that we or our licensees may not be able to enroll the required number of subjects in planned clinical trials of our product candidates and that such clinical trials may not be successfully completed, that BioCryst or its licensees may not commence as expected additional human clinical trials with our product candidates, that our product candidates may not receive required regulatory clearances from the FDA, that ongoing and future preclinical and clinical development may not have positive results, that we or our licensees may not be able to continue future development of our current and future development programs, that our development programs may never result in future product, license or royalty payments being received by BioCryst, that BioCryst may not be able to retain its current pharmaceutical and biotechnology partners for further development of its product candidates or it may not reach favorable agreements with potential pharmaceutical and biotec
'/>"/>
SOURCE BioCryst Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza
2. Isolagen to Host Investor Conference Call to Present an Analysis of the Data from Phase III Wrinkle Studies
3. Peregrine Pharmaceuticals Completes Patient Enrollment In First Stage of Bavituximab Phase II Lung Cancer Trial
4. GeoVaxs DNA and MVA Vaccines Shipped to HIV Vaccine Trials Network for Use in the Upcoming Phase 2a Trial
5. New Data From Head-to-Head Phase 3 Trial Demonstrate That Liraglutide is More Effective Than Exenatide in Treatment of Type 2 Diabetes
6. Nile Therapeutics Announces Positive Interim Data from Phase 2a Study of CD-NP in Patients with Heart Failure
7. Neurobiological Technologies Announces Update Call on Viprinex (TM) Phase 3 Trial Program
8. BioXcel Forms a Corporate Advisory Board for Its Next Phase of Growth
9. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
10. TorreyPines Therapeutics Reports Successful End-of-Phase II Meeting With FDA for Tezampanel
11. AEterna Zentaris Completes Patient Recruitment for Second Efficacy Trial of its Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... PARK, Calif. , Aug. 28, 2014 /PRNewswire/ ... focused on developing novel mid- to late-stage cardiovascular ... $7.0 million in its first round of financing. ... Biomedical Investments and Hercules Bioventures with participation from ... entrepreneur and pharmaceutical executive, Dr. Larry Hsu ...
(Date:8/28/2014)... Earlier this month, a report was created ... U.S. Air Force on the performance of vehicles using ... type of fuel made from mustard seeds, offered great ... America’s Eco friendly future. In fact, every branch of ... independent of foreign oil over the next few years. ...
(Date:8/27/2014)... 27, 2014 Varian Medical Systems today ... current Salt Lake City manufacturing facility and allow for ... to ultimately create 1,000 new full time jobs in ... “Utah is home to hardworking people with immense engineering ... with Varian’s success in the manufacturing of our state-of-the-art ...
(Date:8/27/2014)... 2014 Reportlinker.com announces that a ... its catalogue: Global Biodegradable Packaging ... http://www.reportlinker.com/p02316661/Global-Biodegradable-Packaging-Materials-Market-2014-2018.html About Biodegradable Packaging ... readily decomposed by the action of microorganisms. ... in terms of raw materials, production technology, ...
Breaking Biology Technology:Armetheon Completes $7.0 Million Series A Financing 2Armetheon Completes $7.0 Million Series A Financing 3Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 2Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 3Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 4Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 5Varian Medical Systems Groundbreaking on Facility Expansion Triggers Influx of New Jobs to Salt Lake 2Varian Medical Systems Groundbreaking on Facility Expansion Triggers Influx of New Jobs to Salt Lake 3Global Biodegradable Packaging Materials Market 2014-2018 2Global Biodegradable Packaging Materials Market 2014-2018 3Global Biodegradable Packaging Materials Market 2014-2018 4Global Biodegradable Packaging Materials Market 2014-2018 5Global Biodegradable Packaging Materials Market 2014-2018 6Global Biodegradable Packaging Materials Market 2014-2018 7
(Date:8/27/2014)... of fish began exploring land and evolved into tetrapods ... ancient fish used their fishy bodies and fins in a ... scientific mysteries. , Researchers at McGill University published in ... called Polypterus , to help show what might have ... water. Polypterus is an African fish that can ...
(Date:8/27/2014)... when it only requires nerve cells to rearrange existing ... to generate new patterns, a study of monkeys has ... through recordings of electrical activity of brain cell networks. ... of Health. , "We looked into the brain and ... outside the box," said Aaron Batista, Ph.D., an assistant ...
(Date:8/27/2014)... manipulating neural circuits in the brain of mice, ... memories. The research, led by Howard Hughes Medical ... of Technology (MIT), reveals that the connections between ... information about an experience and the part of ... that experience are malleable. , Altering those ...
Breaking Biology News(10 mins):Walking fish reveal how our ancestors evolved onto land 2Scientists plug into a learning brain 2Scientists plug into a learning brain 3Researchers change the emotional association of memories 2Researchers change the emotional association of memories 3Researchers change the emotional association of memories 4
... the lichen Phylloblastia fortuita , new to the Iberian ... Phylloblastia dispersa , is also a new entry for ... outside the tropics. Foliicolous lichens, symbiosis between fungi ... and their presence in environments such as the Iberian Peninsula, ...
... January 11, 2010 New standards to help ensure ... widely used in infant formulas and a variety of ... Food Chemicals Codex (FCC), an internationally recognized compendium of ... for three nucleotides, present in breast milk and commonly ...
... , REDWOOD CITY, Calif. and NEW YORK, ... identity and authentication solutions, has extended its leadership in ... , a leading developer of point-of-sale (POS) and retail ... America, has integrated U.are.U® fingerprint biometrics from ...
Cached Biology News:A new species of lichen discovered in the Iberian Peninsula 2Quality and safety of infant formulas, functional foods enhanced by new standards 2Quality and safety of infant formulas, functional foods enhanced by new standards 3Retail Anywhere Adds U.are.U Biometrics From DigitalPersona to Flagship Point of Sale Solution 2Retail Anywhere Adds U.are.U Biometrics From DigitalPersona to Flagship Point of Sale Solution 3
AdestaTM Tissue/Cell Preservation Medium Sterile / Non-sterile: Sterility Tested Endotoxin: ...
...
...
... recognizes 30% of IgM-rheumatoid factor ... does not cross-react with IgM, IgA, ... nor with pooled F(Ab)2 fragments. This ... to detect rheumatoid factor. Product Category: ...
Biology Products: